Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study

Correction Clinical Neurology

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies (vol 22, 141, 2021)

Stephanie J. Nahas et al.

JOURNAL OF HEADACHE AND PAIN (2022)

Article Clinical Neurology

Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study

Alicia Gonzalez-Martinez et al.

Summary: This study utilized machine learning models to predict the efficacy of anti-CGRP therapies at 6, 9, and 12 months for migraine patients, providing a predictive tool that can be applied in real-world settings.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study

Ilaria Cetta et al.

Summary: This study evaluated and compared the real-life efficacy and safety of anti-CGRP monoclonal antibodies (mAbs) in young and elder migraine patients, finding similar effectiveness and safety in patients aged over 65 and under 65.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Piero Barbanti et al.

Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

HEADACHE (2021)

Add to Collection

Article Clinical Neurology

Hypertension: A new safety risk for patients treated with erenumab

Suprat Saely et al.

Summary: This study analyzed 61 postmarketing case reports of elevated blood pressure associated with erenumab use, with most cases occurring in women within a week of initial dose. Some cases had serious outcomes, including hospitalization, but there were no reported deaths.

HEADACHE (2021)

Add to Collection

Review Clinical Neurology

Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis

Prashant Soni et al.

Summary: This systematic review and network meta-analysis examined the effects of anti-calcitonin gene related peptide monoclonal antibodies on adult patients with chronic migraine. The results indicated that high doses of subcutaneous fremanezumab and intravenous eptinezumab showed numerical advantages in reducing migraine days. Additionally, anti-CGRP mAbs were found to have comparable safety and immunogenicity, with no significant differences observed.

CLINICAL NEUROLOGY AND NEUROSURGERY (2021)

Add to Collection

Article Clinical Neurology

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months

Edoardo Caronna et al.

Summary: In real-life clinical practice, anti-CGRP monoclonal antibodies are effective in chronic migraine patients with medication overuse as well as those without it, leading to a reduction in headache frequency and acute medication use. The choice of different monoclonal antibodies does not affect the resolution of medication overuse, and patients with lower pain severity at baseline are more likely to stop overusing medications.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Clinical Neurology

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri et al.

Summary: In real-life settings, galcanezumab showed significant effectiveness in preventing HFEM and CM by reducing the number of migraine days and headache intensity, with good safety and tolerability. Patients who responded well to galcanezumab tended to have normal weight and a history of fewer failed preventive treatments.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Clinical Neurology

The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study

Marta Torres-Ferrus et al.

Summary: The study evaluated the response to monoclonal antibodies against calcitonin gene-related peptide in refractory migraine patients. The results showed a significant reduction in headache and migraine frequency, with a high percentage of patients achieving a ≥50% reduction in migraine days per month. The treatment was effective and well-tolerated in this population.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

Messoud Ashina et al.

Summary: Fremanezumab is an injectable biologic medication used for preventing migraine attacks, with the main goals of reducing migraine days and disability, evaluating patient adherence to treatment plans, and assessing treatment discontinuation.

PAIN MANAGEMENT (2021)

Add to Collection

Article Clinical Neurology

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Messoud Ashina et al.

Summary: Fremanezumab showed sustained efficacy for up to 6 months and was well tolerated in patients with episodic or chronic migraine who had inadequate response to multiple preventive medications. Patients receiving monthly or quarterly doses of fremanezumab experienced improvements in migraine days, disability scores, and other migraine-related symptoms with low rates of adverse events leading to discontinuation.

JOURNAL OF HEADACHE AND PAIN (2021)

Add to Collection

Article Clinical Neurology